drugset / Trial / NCT00828074
Sorafenib and Vinorelbine in Treating Women With Stage IV Breast Cancer
Phase 1/2
Completed
46 enrolled
City of Hope Medical Center
National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as vinorelbine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving sorafenib together with vinorelbine may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of sorafenib when given together with vinorelbine and to see how well they work in treating women with stage IV breast cancer.
Timeline
- Start
- 2008-11
- Primary completion
- 2014-04
- Completion
- 2014-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sorafenib | Small molecule | 200 mg | Oral |
| Subject | Sorafenib | Small molecule | 400 mg | Oral |
| Subject | Vinorelbine | Small molecule | 20 mg/m2 | Intravenous |
| Subject | Vinorelbine | Small molecule | 25 mg/m2 | Intravenous |